Vivo Bio Tech Share Price

Vivo Bio Tech Limited, established in February, 1987 is a full service CRO offering drug development discovery services to pharmaceutical biotech companies worldwide in accordance with OECD, AAALAC IND guidelines. The company offers services in the areas of In vitro, In vivo, toxicity studies, pharmacological investigations, pharmacokinetics toxicokinetic studies etc. Their experienced talented scientists offer advice on defining drug development paths tailored to specific molecules.The Company stands as a premier and primary provider of SPF lab animals in India. It holds the distinction of being the largest breeder and distributor of rodent models, in addition to offering custom rodent models and stem cell products through Cyagen Biosciences. The Company serves as an authorized distributor of lab animal diets from Special Diets Services (UK) in India. It pioneered the commercial distribution of SPF guinea pigs, sourcing breeders from Elm Hill Labs (USA). Employing topquality SPF breed in their inhouse lab animals, the Company upholds excellence in all pre clinical studies. Their comprehensive services span a wide array of preclinical toxicology disciplines, encompassing Invitro and Invivo studies, analytical chemistry studies, bioanalytical studies, and physicochemical studies. Moreover, the Company boasts supplementary satellite facilities situated in Pregnapur Village, Siddipet District, Hyderabad, Telangana. The Biologic Research Services group at Vivo Bio Tech offers a complete line of protein services, including gene synthesis, cloning, expression and purification of recombinant proteins and monoclonal antibodies. Invitro Services offers solutions for pharmacologic, toxicological bio analytical investigations in drug discovery development. Critical investigations like bacterial reverse mutation assays, chromosomal aberration, and micronucleus are specialty services by the scientists.The Invivo Services group at Vivo Bio Tech provides both nonregulatory and regulatory IND enabling pre clinical development services. We are capable of screening evaluating molecules for various pharmacological therapeutic properties. Specifically for oncology, scientists provide design development of xenograft models for evaluation of anticancer agents. Further, scientists customize invivo DMPK studies to help drug candidate in both rodent and nonrodent animal models.Vivo Bio has partnered with Taconic for sourcing foundation and expansion colonies of the animal models and have started inhouse breeding of Specific Pathogen Free rodents.The Company partnered Cyagen Biosciences to access genomic technologies in 2016. It commenced breeding and distribution of SPF guinea pigs in 2017. The Company acquired 100% shareholding in M/s. Donakanti Consulting Services Private Ltd on 17 April, 2019. It received ISO 9001:2015 Certification for Quality Management System. The Company completed NGCMA OECD GLP Surveillance and Scope Extension with the introduction of inhalational studies in 2019.The Company transformed from an animal breeding and distributing company into a full service CRO with interest in Invitro, Invivo, EcoTox, Analytical, Bio Analytical and Physchem, ADME and PKPD studies in 202122.

For the full year FY2025–2026, revenue reached ₹51.48 crore and profit touched at ₹7.28 crore.

As of 20 Jan 2026, Vivo Bio Tech share price is ₹29.7. The stock opened at ₹29 and had closed at ₹30.2 the previous day. During today’s trading session, Vivo Bio Tech share price moved between ₹29.02 and ₹30.90, with an average price for the day of ₹29.96. Over the last 52 weeks, the stock has recorded a low of ₹25.21 and a high of ₹56.47. In terms of performance, Vivo Bio Tech share price has declined by 17.4% over the past six months and has declined by 32.3% over the last year.